What is the 13F Pro Quality Score for SDGR?

13F Pro ranks Schrodinger, Inc. (SDGR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SDGR's current score at https://13fpro.ai/research/SDGR (free sign-up required for the full ranking).

Which hedge funds own the most SDGR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SDGR include BlackRock,, GATES FOUNDATION, Rubric Capital Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SDGR as soon as new 13F filings post.

Where does 13F Pro source SDGR data?

All Schrodinger, Inc. fundamentals and ownership data come directly from SEC EDGAR. Schrodinger, Inc. files with the SEC under CIK 1490978. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SDGR in?

Schrodinger, Inc. (SDGR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SDGR research updated on 13F Pro?

SDGR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Schrodinger, Inc.(SDGR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1490978 SDGR stock profile & AI dashboard →

13F Pro Quality Score

31.0/100

Rank #2,333 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

70.9/100

Profitability

8.2/100

Balance Sheet

8.5/100

Earnings Quality

30.0/100

Free Cash Flow

50.5/100

Institutional Flow

8.7/100

Revenue Scale

25.7/100

Dilution Risk

11.3/100

SDGR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Schrodinger, Inc. (SDGR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SDGR at 31.0/100 on a 32-signal composite quality model, placing it at rank #2,333 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (8.2) and balance sheet strength (8.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Schrodinger, Inc. reports quarterly revenue of $58.6M, net income of $-60.0M, an operating margin of -83.3%. Top institutional holders of SDGR by reported 13-F value include BlackRock,, GATES FOUNDATION, Rubric Capital Management, based on the most recent SEC filings. SDGR trades on the Nasdaq exchange and files with the SEC under CIK 1490978. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SDGR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Schrodinger, Inc. directly from SEC EDGAR. Schrodinger, Inc.'s 13F Pro composite quality score has ranged between 8 and 55 since 2021, currently 31.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Schrodinger, Inc.

Quirks, history, and lore behind SDGR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life-sciences software company · listed on Nasdaq · applies computational chemistry and physics-based simulation to drug discovery.
2
The Numbers
Annual revenue in the range of $150–200 million — small-cap territory — with a cloud-hosted software platform that serves most of the world's top pharmaceutical companies.
3
The History
Founded in 2010 as a spinout of technology originally developed at academia, it went public in 2020 during the biotech IPO boom and quickly became a darling of the AI-in-drug-discovery narrative.
4
The Secret
The company doesn't just sell software — it also co-discovers drugs itself, taking milestone payments and royalties if a molecule it helped design ever reaches patients.
5
The Lore
Its platform is named LiveDesign, and its molecular simulation engine is so computationally intense it was an early showcase customer for GPU-accelerated cloud computing.
6
The Giveaway
Named after the physicist famous for a thought experiment involving a cat that is simultaneously alive and dead — which, coincidentally, is also how investors feel about its stock.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$58.6M

Net Income

Q1 2026

$-60.0M

Free Cash Flow

Q1 2026

$-17.3M

Operating Margin

Q1 2026

-83.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-4.2% YoY

$207.5MFY 2024

FY21 $137.9MFY22 $181.0MFY23 $216.7MFY24 $207.5M

Net Income

-559.5% YoY

$-187.1MFY 2024

FY21 $-100.4MFY22 $-149.2MFY23 $40.7MFY24 $-187.1M

Operating Income

-17.9% YoY

$-209.3MFY 2024

FY21 $-111.4MFY22 $-146.8MFY23 $-177.4MFY24 $-209.3M

EPS (Diluted)

-575.9% YoY

$-2.57FY 2024

FY21 $-1.42FY22 $-2.10FY23 $0.54FY24 $-2.57

Total Assets

+2.5% YoY

$823.2MFY 2024

FY21 $756.5MFY22 $688.6MFY23 $803.0MFY24 $823.2M

Op. Cash Flow

-15.1% YoY

$-157.4MFY 2024

FY21 $-70.7MFY22 $-119.7MFY23 $-136.7MFY24 $-157.4M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$207.5M -4.2%	$216.7M +19.7%	$181.0M +31.2%	$137.9M +27.6%	$108.1M +26.4%	$85.5M
Net Income	$-187.1M -559.5%	$40.7M +127.3%	$-149.2M -48.6%	$-100.4M -310.4%	$-24.5M +0.4%	$-24.6M
Operating Income	$-209.3M -17.9%	$-177.4M -20.9%	$-146.8M -31.7%	$-111.4M -82.9%	$-60.9M -57.3%	$-38.7M
EPS (Diluted)	$-2.57 -575.9%	$0.54 +125.7%	$-2.10 -47.9%	$-1.42 -246.3%	$-0.41	—
Total Assets	$823.2M +2.5%	$803.0M +16.6%	$688.6M -9.0%	$756.5M +1.4%	$746.3M +380.6%	$155.3M
Operating Cash Flow	$-157.4M -15.1%	$-136.7M -14.2%	$-119.7M -69.4%	$-70.7M -521.7%	$16.8M +164.3%	$-26.1M

AI Insight: SDGR Financial Trends

Schrodinger posted its first profitable quarter in Q4 2025 with $33M net income, but immediately returned to losses in Q1 2026.

• Revenue shows seasonal pattern with Q4 spikes to $88M (2024) and $87M (2025) versus weaker quarters.

• Operating losses improved from $-68M in Q3 2024 to $-17M in Q4 2025 before deteriorating to $-49M in Q1 2026.

• Equity declined consistently from $474M in Q2 2024 to $314M in Q1 2026, reflecting cumulative losses.

⚠ Q1 2026 return to $-60M net loss after Q4 2025 profitability raises sustainability concerns about the turnaround.

⚠ Operating cash flow turned sharply negative to $-62M in Q3 2025 from positive $144M in Q1 2025.

AI Insight: SDGR Ratio Trends

Schrodinger shows extreme quarterly volatility with operating margins swinging from positive in Q4 2025 to deeply negative in Q1 2026.

• Operating margin improved dramatically from -193.9% in Q3 2024 to -19.7% in Q4 2025 before deteriorating to -83.3% in Q1 2026.

• Net profit margin turned positive at 37.3% in Q4 2025, the only profitable quarter in the dataset.

• ROE swung from positive 35.7% in Q4 2025 to deeply negative -76.6% in Q1 2026.

⚠ Extreme quarterly earnings volatility suggests inconsistent business model or significant one-time items affecting profitability.

⚠ ROIC remains consistently negative across all quarters except brief improvement in Q4 2025 to -18.9%.

Get alerted when SDGR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Schrodinger, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SDGR

BlackRock, Inc.
$109.9M9,678,560 sh
GATES FOUNDATION TRUST
$79.3M6,981,664 sh
Rubric Capital Management LP
$68.2M6,000,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$43.9M3,862,197 sh
Nikko Asset Management Americas, Inc.
$36.2M3,190,837 sh
Sumitomo Mitsui Trust Holdings, Inc.
$36.2M3,190,837 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$30.5M2,684,692 sh
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$30.2M2,660,283 sh
VANGUARD CAPITAL MANAGEMENT LLC
$29.6M2,604,374 sh
STATE STREET CORP
$24.9M2,191,427 sh

Fund	Value	Shares
BlackRock, Inc.	$109.9M	9,678,560
GATES FOUNDATION TRUST	$79.3M	6,981,664
Rubric Capital Management LP	$68.2M	6,000,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$43.9M	3,862,197
Nikko Asset Management Americas, Inc.	$36.2M	3,190,837
Sumitomo Mitsui Trust Holdings, Inc.	$36.2M	3,190,837
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$30.5M	2,684,692
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME	$30.2M	2,660,283
VANGUARD CAPITAL MANAGEMENT LLC	$29.6M	2,604,374
STATE STREET CORP	$24.9M	2,191,427

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SDGR on your watchlist

Track score changes the day Schrodinger, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SDGR a good stock to buy?

13F Pro's AI-powered analysis of Schrodinger, Inc. (SDGR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SDGR are available on the SDGR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SDGR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SDGR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Schrodinger, Inc.'s investment landscape.